ORIC Pharmaceuticals plans Phase 3 enozertinib trial in lung cancer for first half of 2027

By Public Technologies
  • ORIC Pharmaceuticals plans to start Redwood-1, a global Phase 3 trial of enozertinib in first-line EGFR atypical lung cancer, in first-half 2027.
  • Phase 1b results presented at ESMO Congress 2026 showed tumor shrinkage, including brain metastases, with some brain tumors disappearing completely.
  • Treatment-related side effects caused no discontinuations; survival and response-duration findings remain immature.
  • The planned trial will enroll approximately 360 patients, comparing enozertinib with physician-selected osimertinib or afatinib.
  • Response results could support accelerated approval, while progression-free survival will underpin the full-approval assessment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oric Pharmaceuticals Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610230315PRIMZONEFULLFEED9851709) on October 23, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk